Immunic (IMUX) Share-based Compensation (2013 - 2026)

Immunic has reported Share-based Compensation for 14 years, with the latest figure at $4.5 million in Q1 2026.

• Quarterly Share-based Compensation rose 118.71% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (down 24.53% YoY) and the FY2024 annual result came in at $448000.0, down 17.65% from the prior year.
• Share-based Compensation improved to $4.5 million in Q1 2026 per IMUX's latest filing, from -$7.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $2.1 billion in Q3 2025 and troughed at -$7.6 million in Q4 2025.
• A 5-year average of $619.2 million and a median of $4.5 million in 2026 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation surged 135.03% in 2023, then sank 99.77% in 2025.
• Over 5 years, Share-based Compensation stood at $1.9 million in 2022, then jumped by 43113.15% to $815.0 million in 2023, then plunged by 100.75% to -$6.1 million in 2024, then dropped by 23.97% to -$7.6 million in 2025, then soared by 159.11% to $4.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $4.5 million, -$7.6 million, and $2.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.